Lannett Company, Inc. (LCI)

NYSE - NYSE Real Time Price. Currency in USD
21.40-0.65 (-2.95%)
At close: 4:01 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close22.05
Bid21.00 x 100
Ask21.65 x 500
Day's Range21.30 - 22.30
52wk Range16.91 - 49.44
1y Target EstN/A
Market Cap789.5M
P/E Ratio (ttm)17.83
Avg Vol (3m)1,025,258
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Moody's16 hours ago

    Mallinckrodt plc -- Moody's: FDA Proposal to withdraw generic Concerta from the market would be negative for Lannett and Mallinckrodt

    New York, October 21, 2016-- Moody's Investors Service commented that the Food and Drug Administration's proposal to withdraw approval of the Abbreviated New Drug Applications for methylphenidate HCl ER ...

  • American City Business Journals3 days ago

    FDA to withdraw approval of Lannett's generic ADHD drug

    The Food and Drug Administration has notified Lannett Co. Inc. that the agency intends to withdraw its approval of the company’s methylphenidate hydrochloride extended-release tablets used to treat attention deficit hyperactivity disorder. The product in question is a generic version of Concerta, an ADHD drug marketed by Johnson & Johnson (JNJ) subsidiary Janssen Pharmaceuticals. The FDA’s decision to withdraw approval of two company’s products came after patients reported that the therapeutics benefits of extended-release generic tablets of the drug — one made by UCB/Kremers Urban Pharmaceuticals and one made by Mallinckrodt Pharmaceuticals — would wear off faster than those provided by the brand-name version.

  • PR Newswire3 days ago

    Lannett Comments On FDA Proposal Regarding Methylphenidate Extended Release Tablets

    PHILADELPHIA, Oct. 19, 2016 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) received a notice from the U.S. Food and Drug Administration (FDA) that it will seek to withdraw approval of the Company's ...